Points to consider regarding the use and implementation of virtual controls in nonclinical general toxicology studiesREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52024-06-018PRE
Characterization of Anticancer Effects of the Analogs of DJ4, a Novel Selective Inhibitor of ROCK and MRCK KinasesPHARMACEUTICALSIF4.82023-07-261OAAI
Evaluation of chronic toxicity of cyclocreatine in beagle dogs after oral gavage administration for up to 23 weeksTOXICOLOGY AND APPLIED PHARMACOLOGYIF3.42021-11-013OAAI
Old drugs, new uses: Drug repurposing in hematological malignanciesSEMINARS IN CANCER BIOLOGYIF15.72021-01-0129PREAI
Evaluation of chronic toxicity of cyclocreatine, a creatine analog, in Sprague Dawley rat after oral gavage administration for up to 26 weeksREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52020-11-016PREAI
Preclinical toxicity evaluation of JD5037, a peripherally restricted CB1 receptor inverse agonist, in rats and dogs for treatment of nonalcoholic steatohepatitisREGULATORY TOXICOLOGY AND PHARMACOLOGYIF3.52019-12-0121OAAI
In vitro characterization of novel inhibitors of ROCK and MRCK kinases as anticancer agentsCANCER RESEARCHIF16.62016-07-150PRE
Targeting of chemokine receptor CXCR4 inhibits invasion and sensitizes melanoma cells to chemotherapeutic agentsCANCER RESEARCHIF16.62015-08-010PRE
The apoptotic mechanism of action of SKI-178, a novel Sphingosine kinase 1 selective inhibitorCANCER RESEARCHIF16.62015-08-010PRE
The regulatory roles of ROCK and MRCK kinases in the plasticity of cancer cell migrationCANCER LETTERSIF10.12015-06-0141PREAI
The Apoptotic Mechanism of Action of the Sphingosine Kinase 1 Selective Inhibitor SKI-178 in Human Acute Myeloid Leukemia Cell LinesJOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICSIF3.82015-03-0144OAAI
A novel selective multikinase inhibitor of ROCK and MRCK effectively blocks cancer cell migration and invasionCANCER LETTERSIF10.12014-11-0125OAAI
Gambogic acid inhibits chemokine receptor CXCR4 signaling pathways and osteoclastogenesis in multiple myelomaCANCER RESEARCHIF16.62014-10-010PRE